<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39415197</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6150</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>Biology direct</Title><ISOAbbreviation>Biol Direct</ISOAbbreviation></Journal><ArticleTitle>Characterization of the symmetrical benzimidazole twin drug TL1228: the role as viral entry inhibitor for fighting COVID-19.</ArticleTitle><Pagination><StartPage>93</StartPage><MedlinePgn>93</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">93</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13062-024-00523-9</ELocationID><Abstract><AbstractText>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is reliably one of the largest pandemics the world has suffered in recent years. In the search for non-biological antivirals, special emphasis was placed on drug repurposing to accelerate the clinical implementation of effective drugs.The life cycle of the virus has been extensively investigated and many human targets have been identified, such as the molecular chaperone GRP78, representing a host auxiliary factor for SARS-CoV-2 entry. Here we report the inhibitor capacity of TL1228, a small molecule discovered through an in silico screening approach, which could interfere with the interaction of SARS-CoV-2 and its target cells, blocking the recognition of the GRP78 cellular receptor by the viral Spike protein. TL1228 showed in vitro the ability to reduce significantly both pseudoviral and authentic viral activity even through the reduction of GRP78/ACE2 transcript levels. Importantly, TL1228 acts in modulating expression levels of innate immunity and as inflammation markers.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Murdocca</LastName><ForeName>Michela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Andrade Santos-Filho</LastName><ForeName>Osvaldo</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Center of Health Sciences Laboratory of Molecular Modelling &amp; Computational Strutural Biology Cidade Universitária, Federal University of Rio de Janeiro IPPN, Av. Carlos Chagas Filho373, Bloco H, Rio de Janeiro, 21941-599, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Masi</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dos Santos Rodrigues</LastName><ForeName>Edivaldo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center of Health Sciences Laboratory of Molecular Modelling &amp; Computational Strutural Biology Cidade Universitária, Federal University of Rio de Janeiro IPPN, Av. Carlos Chagas Filho373, Bloco H, Rio de Janeiro, 21941-599, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campos de Souza</LastName><ForeName>Claudia Valeria</ForeName><Initials>CV</Initials><AffiliationInfo><Affiliation>Center of Health Sciences Laboratory of Molecular Modelling &amp; Computational Strutural Biology Cidade Universitária, Federal University of Rio de Janeiro IPPN, Av. Carlos Chagas Filho373, Bloco H, Rio de Janeiro, 21941-599, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Santis</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Public Health and Infectious Diseases, University of Rome Sapienza, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Defence Institute for Biomedical Sciences, Rome, 00184, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amatore</LastName><ForeName>Donatella</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Defence Institute for Biomedical Sciences, Rome, 00184, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latini</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schipani</LastName><ForeName>Rossella</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>di Rienzo Businco</LastName><ForeName>Lino</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Otorhinolaryngology Department, Institute of Sport Medicine and Science CONI, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandimarte</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Electronic Measurements Physics Department, Sapienza University, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grilli</LastName><ForeName>Giorgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Defence Institute for Biomedical Sciences, Rome, 00184, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Tien L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Formerly Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, 1 Drexel Drive, New Orleans, LA, 70125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayence</LastName><ForeName>Annie S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Formerly Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, 1 Drexel Drive, New Orleans, LA, 70125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lista</LastName><ForeName>Florigio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Defence Institute for Biomedical Sciences, Rome, 00184, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duranti</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, 61029, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sangiuolo</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy. sangiuolo@med.uniroma2.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanden Eynde</LastName><ForeName>Jean Jacques</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Formerly Department of Organic Chemistry (FS), University of Mons-UMONS, 1 place du Parc, Mons, 7000, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novelli</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HORIZON-HLTL-2021 project "UNDINE" (101057100)</GrantID><Agency>ERC</Agency><Country /></Grant><Grant><GrantID>HORIZON-HLTL-2021 project "UNDINE" (101057100)</GrantID><Agency>ERC</Agency><Country /></Grant><Grant><GrantID>HORIZON-HLTL-2021 project "UNDINE" (101057100)</GrantID><Agency>ERC</Agency><Country /></Grant><Grant><GrantID>HORIZON-HLTL-2021 project "UNDINE" (101057100)</GrantID><Agency>ERC</Agency><Country /></Grant><Grant><GrantID>MUR program PNRR M4-C2-I1.1 PRIN2022 "HECORES" (2022ZSLRPT)</GrantID><Agency>Italian Ministry of Research</Agency><Country /></Grant><Grant><GrantID>MUR program PNRR M4-C2-I1.1 PRIN2022 "HECORES" (2022ZSLRPT)</GrantID><Agency>Italian Ministry of Research</Agency><Country /></Grant><Grant><GrantID>MUR program PNRR M4-C2-I1.1 PRIN2022 "HECORES" (2022ZSLRPT)</GrantID><Agency>Italian Ministry of Research</Agency><Country /></Grant><Grant><GrantID>MUR program PNRR M4-C2-I1.1 PRIN2022 "HECORES" (2022ZSLRPT)</GrantID><Agency>Italian Ministry of Research</Agency><Country /></Grant><Grant><GrantID>Prot. n°2885/2022</GrantID><Agency>Nutrintech Med Italia (Rome, I)</Agency><Country /></Grant><Grant><GrantID>Prot. n°2885/2022</GrantID><Agency>Nutrintech Med Italia (Rome, I)</Agency><Country /></Grant><Grant><GrantID>Prot. n°2885/2022</GrantID><Agency>Nutrintech Med Italia (Rome, I)</Agency><Country /></Grant><Grant><GrantID>Prot. n°2885/2022</GrantID><Agency>Nutrintech Med Italia (Rome, I)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Biol Direct</MedlineTA><NlmUniqueID>101258412</NlmUniqueID><ISSNLinking>1745-6150</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000091342">Endoplasmic Reticulum Chaperone BiP</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000717247">HSPA5 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000091342" MajorTopicYN="Y">Endoplasmic Reticulum Chaperone BiP</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001562" MajorTopicYN="Y">Benzimidazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="Y">Virus Internalization</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006360" MajorTopicYN="N">Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3CLpro</Keyword><Keyword MajorTopicYN="N">Benzimidazole drug</Keyword><Keyword MajorTopicYN="N">GRP78</Keyword><Keyword MajorTopicYN="N">Molecular docking</Keyword><Keyword MajorTopicYN="N">Molecular dynamics</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>23</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39415197</ArticleId><ArticleId IdType="pmc">PMC11481581</ArticleId><ArticleId IdType="doi">10.1186/s13062-024-00523-9</ArticleId><ArticleId IdType="pii">10.1186/s13062-024-00523-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fernandes Q, Inchakalody VP, Merhi M, Mestiri S, Taib N, Moustafa A, El-Ella D, et al. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Ann Med. 2022;54:524–40. 10.1080/07853890.2022.2031274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8843115</ArticleId><ArticleId IdType="pubmed">35132910</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J. COVID-19 is surging again-with far fewer serious cases. Science. 2024;385:814–5. 10.1126/science.ads6028.</Citation><ArticleIdList><ArticleId IdType="pubmed">39172845</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Liu B, Li C, Wang Y, Geng S, Du X, et al. Stem cell-based therapy for COVID-19. Int Immunopharmacol. 2023;124:110890. 10.1016/j.intimp.2023.110890.</Citation><ArticleIdList><ArticleId IdType="pubmed">37688914</ArticleId></ArticleIdList></Reference><Reference><Citation>Mongin D, Bürgisser N, Laurie G, Schimmel G, Vu DL, Cullati S, et al. Effect of SARS-CoV-2 prior infection and MRNA vaccination on contagiousness and susceptibility to infection. Nat Commun. 2023;14:1–13. 10.1038/s41467-023-41109-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10482859</ArticleId><ArticleId IdType="pubmed">37673865</ArticleId></ArticleIdList></Reference><Reference><Citation>Martín Sánchez FJ, Martínez-Sellés M, Molero García JM, Moreno Guillén S, Rodríguez-Artalejo FJ, Ruiz-Galiana J, et al. Insights for COVID-19 in 2023. Rev Esp Quimioter. 2023;36:114–24. 10.37201/req/122.2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10066911</ArticleId><ArticleId IdType="pubmed">36510683</ArticleId></ArticleIdList></Reference><Reference><Citation>Mykytyn AZ, Fouchier RA, Haagmans BL. Antigenic evolution of SARS Coronavirus 2. Curr Opin Virol. 2023;62:101349. 10.1016/j.coviro.2023.101349.</Citation><ArticleIdList><ArticleId IdType="pubmed">37647851</ArticleId></ArticleIdList></Reference><Reference><Citation>Peleman C, Van Coillie S, Ligthart S, Men Choi S, De Waele J, Depuydt P. Ferroptosis and pyroptosis signatures in critical COVID-19 patients cell death Differ. 2023, 9, 2066–77. 10.1038/s41418-023-01204-2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10482958</ArticleId><ArticleId IdType="pubmed">37582864</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Liu Y, Huang Z, Xu W, Hu W, Yi L, et al. SARS-CoV-2 non-structural protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1. Cell Death Differ. 2022;29:1240–54. 10.1038/s41418-021-00916-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9177730</ArticleId><ArticleId IdType="pubmed">34997207</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A, Morrone MC, Patrono C, Santoro MG, Schiaffino S, Remuzzi G, Bussolati G. Covid-19 Commission of the Accademia Nazionale dei Lincei.Long covid: where we stand and challenges ahead. Cell Death Differ. 2022;29:1891–900. 10.1038/s41418-022-01052-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9449925</ArticleId><ArticleId IdType="pubmed">36071155</ArticleId></ArticleIdList></Reference><Reference><Citation>Arman BY, Brun J, Hill ML, Zitzmann N, von Delft A. An update on SARS-CoV-2 clinical trial results—what we can learn for the next pandemic. Int J Mol Sci. 2023;25:354. 10.3390/ijms25010354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10779148</ArticleId><ArticleId IdType="pubmed">38203525</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Wang Y, Sun Q, Knopf J, Herrmann M, Lin L, et al. Immune response in COVID-19: what is next? Cell Death Differ. 2022;6:1107–22. 10.1038/s41418-022-01015-x.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9110941</ArticleId><ArticleId IdType="pubmed">35581387</ArticleId></ArticleIdList></Reference><Reference><Citation>André S, Picard M, Cezar R, Roux-Dalvai F, Alleaume-Butaux A, Soundaramourty C, et al. T cell apoptosis characterizes severe Covid-19 disease. Cell Death Differ. 2022;29:1486–99. 10.1038/s41418-022-00936-x.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8782710</ArticleId><ArticleId IdType="pubmed">35066575</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Wu Y, Meng X, Wang Z, Younis M, Liu Y, et al. SARS-CoV-2 membrane protein causes the mitochondrial apoptosis and pulmonary edema via targeting BOK. Cell Death Differ. 2022;29:1395–408. 10.1038/s41418-022-00928-x.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8752586</ArticleId><ArticleId IdType="pubmed">35022571</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Zhou W, Niu Z, Sun J, Zhang Z, Li Q, et al. Long-range enhancement of N501Y-endowed mouse infectivity of SARS-CoV-2 by the non-RBD mutations of Ins215KLRS and H655Y. Biol. Direct. 2022;17:14. 10.1186/s13062-022-00325-x.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9167559</ArticleId><ArticleId IdType="pubmed">35658928</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlos AJ, Ha DP, Yeh DW, Van Krieken R, Tseng CC, Zhang P. The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection. J Biol Chem. 2021;296:100759. 10.1016/J.JBC.2021.100759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8102082</ArticleId><ArticleId IdType="pubmed">33965375</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei X, Pan C, Zhang X, Zhang W. Total network controllability analysis discovers explainable drugs for Covid-19 treatment. Biol Direct. 2023;18(55). 10.1186/s13062-023-00410-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10478273</ArticleId><ArticleId IdType="pubmed">37670359</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu T, Niu G, Zhang Y, Chen M, Li CY, Hao L, et al. Host-mediated RNA editing in viruses. Biol Direct. 2023. 10.1186/s13062-023-00366-w. ,18,12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10043548</ArticleId><ArticleId IdType="pubmed">36978112</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, Yang X, Lou, Wang XG, Hu B, Zhang L, et al. A Pneumonia Outbreak Associated with a New Coronavirus of probable Bat Origin. Nature. 2020;579:270–3. 10.1038/s41586-020-2012-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Sun S, Du C, Hu K, Zhang C, Liu M, et al. Transmembrane serine protease TMPRSS2 implicated in SARS-CoV-2 infection is Autoactivated intracellularly and requires N-Glycosylation for Regulation. J Biol Chem. 2022;298:102643. 10.1016/j.jbc.2022.102643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9598255</ArticleId><ArticleId IdType="pubmed">36309092</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto M, Kiso M, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, Takeda M, et al. The Anticoagulant Nafamostat Potently inhibits SARS-CoV-2 S protein-mediated Fusion in a cell Fusion Istem and viral infection in Vitro in a cell-type-dependent manner. Viruses. 2020;12:629. 10.3390/v12060629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7354595</ArticleId><ArticleId IdType="pubmed">32532094</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim IM, Abdelmalek DH, Elshahat ME, Elfiky AA. COVID-19 spike-host cell receptor GRP78 binding site prediction. J Infect. 2020;80:554–62. 10.1016/j.jinf.2020.02.026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102553</ArticleId><ArticleId IdType="pubmed">32169481</ArticleId></ArticleIdList></Reference><Reference><Citation>Mody V, Ho J, Wills S, Mawri A, Lawson L, Ebert MCCJC, et al. Identification of 3-Chymotrypsin like protease (3CLPro) inhibitors as potential Anti-SARS-CoV-2 agents. Commun Biol. 2021;4:93. 10.1038/s42003-020-01577-x.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7817688</ArticleId><ArticleId IdType="pubmed">33473151</ArticleId></ArticleIdList></Reference><Reference><Citation>Quimque MTJ, Notarte KIR, Fernandez RAT, Mendoza MAO, Liman RAD, Lim JAK, et al. Virtual screening-driven Drug Discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, Replication, post-translational modification and host immunity evasion infection mechanisms. J Biomol Struct Dyn. 2021;39:4316–33. 10.1080/07391102.2020.1776639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7309309</ArticleId><ArticleId IdType="pubmed">32476574</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasamy S, Subbian S. Critical DetermiIants of Cytokine Storm and Type i Interferon Response in COVID-19 pathogenesis. Clin Microbiol Rev. 2021;34:1–24. 10.1128/CMR.00299-20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8142516</ArticleId><ArticleId IdType="pubmed">33980688</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomassoli I, Gündisch D. The twin drug approach for novel nicotinic acetylcholine receptor ligands. Bioorg Med Chem. 2015;23:4375–89. 10.1016/j.bmc.2015.06.034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4527756</ArticleId><ArticleId IdType="pubmed">26142318</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibacache JA, Faundes J, Montoya M, Mejías S, Valderrama JA. Preparation of Novel Homodimers Derived from Cytotoxic isoquinolinequinones. Twin Drug Approach Molecules. 2018;23:439. 10.3390/molecules23020439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6100386</ArticleId><ArticleId IdType="pubmed">29462956</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Jin Y, Zhang L, Wang H, Wang X. Ninety years of Pentamidine: the development and applications of Pentamidine and its analogs. Curr Med Chem. 2022;29:4602–9. 10.2174/0929867329666220314121446.</Citation><ArticleIdList><ArticleId IdType="pubmed">35289252</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang TL, Mayence A, Vanden Eynde JJ. Some non-conventional biomolecular targets for diamidines. A short survey. Bioorg Med Chem. 2014;22:1983–92. 10.1016/j.bmc.2014.02.049.</Citation><ArticleIdList><ArticleId IdType="pubmed">24630693</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayence A, Pietka A, Collins MS, Cushion MT, Tekwani BL, Huang TL, et al. Novel bisbenzimidazoles with Antileishmanial Effectiveness. Bioorg Med Chem Lett. 2008;18:2658–61. 10.1016/j.bmcl.2008.03.020.</Citation><ArticleIdList><ArticleId IdType="pubmed">18367395</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues L, Cunha RB, Vassilevskaia T, Viveiros M, Cunha C. Drug Repurposing for COVID-19: a review and a Novel Strategy to identify new targets and potential drug candidates. Molecules. 2022;27:2723. 10.3390/molecules27092723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9099573</ArticleId><ArticleId IdType="pubmed">35566073</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulm JW, Nelson SF. COVID-19 drug Repurposing: Summary statistics on current clinical trials and promising untested candidates. Transbound Emerg Dis. 2021;68:313–7. 10.1111/tbed.13710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7362058</ArticleId><ArticleId IdType="pubmed">32619318</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitalieri P, Centofanti F, Murdocca M, Scioli MG, Latini A, Cesare et al. Two different therapeutic approaches for SARS-CoV-2 in hiPSCs-Derived lung organoids. 2022, 11, 1235. 10.3390/cells11071235</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8997767</ArticleId><ArticleId IdType="pubmed">35406799</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdocca M, Citro G, Romeo I, Lupia A, Miersch S, Amadio B, Bonomo A, et al. Peptide platform as a powerful Tool in the fight against Covid-19. Viruses. 2021;13:1–21. 10.3390/v13081667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8402770</ArticleId><ArticleId IdType="pubmed">34452531</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastien D, Ebert MCCJC, Forge D, Toulouse J, Kadnikova N, Perron F, et al. Fragment-based design of symmetrical bis-benzimidazoles as selective inhibitors of the Trimethoprim-Resistant, type II R67 Dihydrofolate Reductase. J Med Chem. 2012;55:3182–92. 10.1021/jm201645r.</Citation><ArticleIdList><ArticleId IdType="pubmed">22424148</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of Mpro from SARS-CoV-2 and Discovery of its inhibitors. Nature. 2020;582:289–93. 10.1038/s41586-020-2223-y.</Citation><ArticleIdList><ArticleId IdType="pubmed">32272481</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Nune M, Zong Y, Zhou L, Liu Q. Close and Allosteric Opening of the Polypeptide-Binding Site in a Human Hsp70 Chaperone BiP. Structure. 2015, 23, 2191–2203. 10.1016/j.str.2015.10.012</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4680848</ArticleId><ArticleId IdType="pubmed">26655470</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res. 2000;28:235–42. 10.1093/nar/28.1.235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC102472</ArticleId><ArticleId IdType="pubmed">10592235</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayly CI, Cieplak P, Cornell WD, Kollman PAA. Well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP Model. J Phys Chem. 1993;97:10269–80. 10.1021/j100142a004.</Citation></Reference><Reference><Citation>Gasteiger J, Marsili M. Iterative Partial Equalization of Orbital Electronegativity-a Rapid Access to Atomic charges. Tetrahedron. 1980;36:3219–28. 10.1016/0040-4020(80)80168-2.</Citation></Reference><Reference><Citation>Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and Multithreading. J Comput Chem. 2010;31:455–61. 10.1002/jcc.21334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041641</ArticleId><ArticleId IdType="pubmed">19499576</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Rauscher S, Nawrocki G, Ran T, Feig M, De Groot BL, et al. CHARMM36m: an Improved Force Field for folded and intrinsically disordered proteins. Nat Methods. 2016;14:71–3. 10.1038/nmeth.4067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5199616</ArticleId><ArticleId IdType="pubmed">27819658</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, et al. Gromacs: high performance Molecular simulations through Multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1–2:19–25. 10.1016/j.softx.2015.06.001.</Citation></Reference><Reference><Citation>Vanommeslaeghe K, Hatcher E, Acharya C, Kundu S, Zhong S, Shim J, et al. CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J Comput Chem. 2010;31:671–90. 10.1002/jcc.21367.CHARMM.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2888302</ArticleId><ArticleId IdType="pubmed">19575467</ArticleId></ArticleIdList></Reference><Reference><Citation>Berendsen HJC, Postma JPM, Van Gunsteren WF, Dinola A, Haak JR. Molecular Dynamics with Coupling to an external bath. J Chem Phys. 1984;81:3684–90. 10.1063/1.448118.</Citation></Reference><Reference><Citation>Parrinello M, Rahman A. Polymorphic transitions in single crystals: a New Molecular Dynamics Method. J Appl Phys. 1981;52:7182–90. 10.1063/1.328693.</Citation></Reference><Reference><Citation>Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG. A smooth particle Mesh Ewald Method. J Chem Phys. 1995;103:8577–93. 10.1063/1.470117.</Citation></Reference><Reference><Citation>Valdés-Tresanco MS, Valdés-Tresanco ME, Valiente PA, Moreno E, gmx_MMPBSA:. A New Tool to perform end-state Free Energy calculations with GROMACS. J Chem Theo Comp. 2021;17:6281–91. 10.1021/acs.jctc.1c00645.</Citation><ArticleIdList><ArticleId IdType="pubmed">34586825</ArticleId></ArticleIdList></Reference><Reference><Citation>Daura X, Gademann K, Jaun B, Seebach D, van Gunnsteren W, Mark A. Peptide folding when simulation meets experiment. Angew Chem. 1999;111:245–9.</Citation></Reference><Reference><Citation>Sander T, Freyss J, Von Korff M, Rufener C, DataWarrior. J Chem Inf Model. 2015;55:460–73. 10.1021/ci500588j. An Open-Source Program for Chemistry Aware Data Visualization and Analysis.</Citation><ArticleIdList><ArticleId IdType="pubmed">25558886</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera - A Visualization System for Exploratory Research and Analysis. J Comput Chem. 2004;25:1605–12. 10.1002/jcc.20084.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris GM, Ruth H, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. Software News and Updates AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30:2785–91. 10.1002/jcc.21256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760638</ArticleId><ArticleId IdType="pubmed">19399780</ArticleId></ArticleIdList></Reference><Reference><Citation>Toulouse JL, Yachnin BJ, Ruediger EH, Deon D, Gagnon M, Saint-Jacques K, et al. Structure-based design of Dimeric Bisbenzimidazole inhibitors to an Emergent Trimethoprim-resistant type II Dihydrofolate Reductase guides the design of Monomeric Analogues. ACS Omega. 2019;4:10056–69. 10.1021/acsomega.9b00640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6648814</ArticleId><ArticleId IdType="pubmed">31460098</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandimarte B, Di Rienzo Businco L, Cappello F, Fiore R, Bastone G, Gualdi G, et al. Nebulization of pharmacological solutions with an innovative medical device based on microvaporization. Heliyon. 2023;9:e14673. 10.1016/j.heliyon.2023.e14673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10068108</ArticleId><ArticleId IdType="pubmed">37020941</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Hilgenfeld R, Whitley R, De Clercq E. Therapeutic strategies for COVID-19: Progress and lessons learned. Nat Rev Drug Discov. 2023;22:449–75. 10.1038/s41573-023-00672-y.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10113999</ArticleId><ArticleId IdType="pubmed">37076602</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao B, Wang Y, Lu H, Huang C, Yang Y, Shang L. Et. Al. Oral simnotrelvir for adult patients with mild-to-moderate Covid-19. N Engl J Med. 2024;390:230–41. 10.1056/NEJMoa2301425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11156186</ArticleId><ArticleId IdType="pubmed">38231624</ArticleId></ArticleIdList></Reference><Reference><Citation>Miersch S, Sharma N, Saberianfar R, Chen C, Caccuri F, Zani A. Ultrapotent and Broad neutralization of SARS-CoV-2 variants by Modular, Tetravalent, Bi-paratopic Antibodies. Cell Rep. 2022;39. 10.1016/j.celrep.2022.110905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9108025</ArticleId><ArticleId IdType="pubmed">35617963</ArticleId></ArticleIdList></Reference><Reference><Citation>Labriola JM, Miersch S, Chen G, Chen C, Pavlenco A, Saberianfar R, et al. Peptide-antibody fusions Engineered by Phage Display exhibit an Ultrapotent and Broad neutralization of SARS-CoV-2 variants. ACS Chem Biol. 2022;17:1978–88. 10.1021/acschembio.2c00411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9236212</ArticleId><ArticleId IdType="pubmed">35731947</ArticleId></ArticleIdList></Reference><Reference><Citation>Pobre KFR, Poet GJ, Hendershot LM. The endoplasmic reticulum (ER) chaperone BiP is a Master Regulator of ER functions: getting by with a little help from ERdj friends. J Biol Chem. 2019;294:2098–108. 10.1074/jbc.REV118.002804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6369273</ArticleId><ArticleId IdType="pubmed">30563838</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabirli R, Koseler A, Goren T, Turkcuer I, Kurt O. High GRP78 levels in Covid-19 infection: a case-control study. Life Sci. 2021;265:118781. 10.1016/j.lfs.2020.118781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674149</ArticleId><ArticleId IdType="pubmed">33220289</ArticleId></ArticleIdList></Reference><Reference><Citation>Versteeg GA, van de Nes PS, Bredenbeek PJ, Spaan WJM. The Coronavirus spike protein induces endoplasmic reticulum stress and upregulation of intracellular chemokine MRNA concentrations. J Virol. 2007;81:10981–90. 10.1128/jvi.01033-07.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2045536</ArticleId><ArticleId IdType="pubmed">17670839</ArticleId></ArticleIdList></Reference><Reference><Citation>Glaab E, Manoharan GB, Abankwa D. A Pharmacophore Model for SARS-CoV-2 3CLpro small molecule inhibitors and in Vitro Experimental Validation of computationally screened inhibitors. J Chem Inf Model. 2021;61:4082–96. 10.1021/acs.jcim.1c00258.</Citation><ArticleIdList><ArticleId IdType="pubmed">34348021</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>